TY - JOUR
KW - Medicaid
KW - buprenorphine
KW - commercial
KW - opioid use disorder
KW - persistence
KW - Predictors
KW - Retention
AU - Natalia Shcherbakova
AU - Gary Tereso
AU - Jacqueline Spain
AU - Robert J. Roose
A1 - 
AB - BACKGROUND: Persistence with medication-assisted therapy among patients with opioid use disorder has been associated with reduced likelihood of illicit opioid use. OBJECTIVE: We aimed to describe treatment persistence and identify factors associated with 1-year persistence among insured patients newly initiating buprenorphine-containing pharmacotherapy. METHODS: The retrospective observational cohort included employer-sponsored and managed Medicaid patients newly started on buprenorphine-containing therapy between June 30, 2010, and January 1, 2015. Persistence was measured as both a continuous and dichotomous variable (proportion of patients persistent for 1 year). Multivariable logistic regression analysis was used to identify factors associated with 1-year persistence. RESULTS: A total of 302 patients met inclusion criteria. The median [range] number of treatment episodes was 1 [1-4]. Mean number of days on therapy during the first episode was 206 (SD = 152) days, with 40.4% (n = 122) of patients persisting for 1 year. Presence of concomitant fills of prescription opioid analgesics (odds ratio [OR] = 0.25; 95% CI = 0.12-0.51), being in care of an addiction specialist (OR = 0.40; 95% CI = 0.21-0.76), and Medicaid insurance coverage (OR = 0.33; 95% CI = 0.13-0.84) were significantly and negatively associated with 1-year persistence. There was also a strong inverse relationship between persistence and inpatient hospitalization (OR = 0.30; 95% CI = 0.12-0.76). CONCLUSIONS: Several health care delivery and use variables were significantly associated with nonpersistence. Concomitant use of prescription opioids is the most easily modifiable risk factor that health care providers and policy makers may act on to improve treatment continuation.
AD - 1 Western New England University College of Pharmacy, Springfield, MA, USA.; 2 Health New England Inc, Springfield, MA, USA.; 2 Health New England Inc, Springfield, MA, USA.; 3 Providence Behavioral Health Hospital, Holyoke, MA, USA.
BT - The Annals of Pharmacotherapy
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 5
CY - United States
DO - 10.1177/1060028017751913
IS - 5
JF - The Annals of Pharmacotherapy
LA - eng
M1 - Journal Article
N2 - BACKGROUND: Persistence with medication-assisted therapy among patients with opioid use disorder has been associated with reduced likelihood of illicit opioid use. OBJECTIVE: We aimed to describe treatment persistence and identify factors associated with 1-year persistence among insured patients newly initiating buprenorphine-containing pharmacotherapy. METHODS: The retrospective observational cohort included employer-sponsored and managed Medicaid patients newly started on buprenorphine-containing therapy between June 30, 2010, and January 1, 2015. Persistence was measured as both a continuous and dichotomous variable (proportion of patients persistent for 1 year). Multivariable logistic regression analysis was used to identify factors associated with 1-year persistence. RESULTS: A total of 302 patients met inclusion criteria. The median [range] number of treatment episodes was 1 [1-4]. Mean number of days on therapy during the first episode was 206 (SD = 152) days, with 40.4% (n = 122) of patients persisting for 1 year. Presence of concomitant fills of prescription opioid analgesics (odds ratio [OR] = 0.25; 95% CI = 0.12-0.51), being in care of an addiction specialist (OR = 0.40; 95% CI = 0.21-0.76), and Medicaid insurance coverage (OR = 0.33; 95% CI = 0.13-0.84) were significantly and negatively associated with 1-year persistence. There was also a strong inverse relationship between persistence and inpatient hospitalization (OR = 0.30; 95% CI = 0.12-0.76). CONCLUSIONS: Several health care delivery and use variables were significantly associated with nonpersistence. Concomitant use of prescription opioids is the most easily modifiable risk factor that health care providers and policy makers may act on to improve treatment continuation.
PP - United States
PY - 2018
SN - 1542-6270; 1060-0280
SP - 405
EP - 414
EP - 
T1 - Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder
T2 - The Annals of Pharmacotherapy
TI - Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 29302989
U3 - 10.1177/1060028017751913
VL - 52
VO - 1542-6270; 1060-0280
Y1 - 2018
Y2 - May
ER -